ArticleThe Journal of urology2023

Safety, Tolerability, and Preliminary Efficacy of TAR-200 in Patients With Muscle-invasive Bladder Cancer Who Refused or Were Unfit for Curative-intent Therapy: A Phase 1 Study.

Mark D Tyson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.